Franklin Resources Inc. decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 11.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 944,437 shares of the medical equipment provider’s stock after selling 118,700 shares during the period. Franklin Resources Inc. owned approximately 0.34% of Hologic worth $40,375,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in HOLX. Parnassus Investments CA lifted its position in Hologic by 88.6% in the fourth quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock valued at $608,797,000 after purchasing an additional 6,689,454 shares during the period. Victory Capital Management Inc. lifted its position in Hologic by 5.8% in the fourth quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock valued at $265,008,000 after purchasing an additional 342,239 shares during the period. Dimensional Fund Advisors LP lifted its position in Hologic by 5.7% in the third quarter. Dimensional Fund Advisors LP now owns 1,969,026 shares of the medical equipment provider’s stock valued at $72,243,000 after purchasing an additional 105,360 shares during the period. Legal & General Group Plc lifted its position in Hologic by 3.5% in the third quarter. Legal & General Group Plc now owns 1,426,469 shares of the medical equipment provider’s stock valued at $52,333,000 after purchasing an additional 48,577 shares during the period. Finally, TD Asset Management Inc. lifted its position in Hologic by 4.8% in the third quarter. TD Asset Management Inc. now owns 1,309,247 shares of the medical equipment provider’s stock valued at $48,036,000 after purchasing an additional 59,865 shares during the period. Institutional investors and hedge funds own 97.56% of the company’s stock.
Hologic stock opened at $38.46 on Monday. Hologic, Inc. has a 1-year low of $35.33 and a 1-year high of $46.80. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.25 and a quick ratio of 0.98. The stock has a market cap of $10,635.31, a PE ratio of 10.15, a price-to-earnings-growth ratio of 1.73 and a beta of 0.84.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The business had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. During the same period last year, the company posted $0.52 EPS. The company’s revenue was up 7.7% on a year-over-year basis. equities research analysts anticipate that Hologic, Inc. will post 2.25 EPS for the current year.
In other Hologic news, Director Namal Nawana acquired 6,600 shares of the company’s stock in a transaction dated Tuesday, February 13th. The stock was acquired at an average cost of $37.88 per share, with a total value of $250,008.00. Following the purchase, the director now directly owns 6,954 shares in the company, valued at approximately $263,417.52. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Charles J. Dockendorff acquired 13,000 shares of the company’s stock in a transaction dated Thursday, March 15th. The shares were acquired at an average cost of $38.80 per share, with a total value of $504,400.00. The disclosure for this purchase can be found here. Company insiders own 0.88% of the company’s stock.
HOLX has been the subject of a number of recent analyst reports. Goldman Sachs upgraded shares of Hologic from a “buy” rating to a “conviction-buy” rating and raised their price objective for the company from $45.00 to $50.00 in a research report on Friday, December 8th. Cowen upgraded shares of Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price objective for the company in a research report on Monday, December 11th. Needham & Company LLC restated a “buy” rating and issued a $50.00 price objective on shares of Hologic in a research report on Thursday, February 1st. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 target price for the company in a report on Thursday, January 4th. Finally, BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $48.00.
TRADEMARK VIOLATION WARNING: “Franklin Resources Inc. Sells 118,700 Shares of Hologic, Inc. (HOLX)” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2018/03/19/franklin-resources-inc-sells-118700-shares-of-hologic-inc-holx.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.